...SAN DIEGO Dec. 11 /- PURE Bioscience(Nasdaq:... (Logo: a href http://www.newscom.com/cgi-bin/prnh/20060119/LATH0...Michael L. Krall President and CEO of PURE Bioscience stated It wa... A number of new partners and distributors have a geographic prese...

SAN DIEGO, Dec. 11 /PRNewswire-FirstCall/ -- PURE Bioscience
(Nasdaq: PURE), creators of the patented silver dihydrogen citrate (SDC)
antimicrobial, today reported revenues for the fiscal quarter ended October
31, 2008 of $110,600 compared with revenues of $95,300 in the same quarter
last year. The Company reported a loss from operations before taxes of
$(1,605,300), or $(0.05) per share, for the current quarter compared with a
loss of $(1,008,700), or $(0.04) per share, in the first fiscal quarter last
year.

Michael L. Krall, President and CEO of PURE Bioscience, stated, "It was
expected that revenues, while reflecting an increase over the year ago quarter
would be down sequentially. As we stated in our recent conference call, the
product needs of our distributors during the early phases of their sales and
marketing launches will vary significantly. In addition, newer distributors
must complete regulatory approval before commercialization, and those
timelines are unpredictable. Accordingly, our quarterly revenue will not
always exhibit linear growth. However, with the maturing of these and
additional product roll outs during the coming quarters, and the expansion of
a more robust partner and distribution pipeline, we are confident in solid
year-over year-growth.

"A number of new partners and distributors have a geographic presence,
market expertise and established sales channels, which will help shorten their
time to market. This pipeline has its foundation in the successful execution
of the three core elements of our business plan: expanding our distribution
network for hard surface disinfectant; developing industry leading alliances,
such as with Rockline Industries and Ciba, to establish and expand commercial
uses of SDC; and establishing strategic partnerships with companies like FTA
Therapeutics to broaden the use of the SDC molecule as an active
pharmaceutical ingredient in medical, dental and veterinary applications."

Krall continued, "SDC is unique because of its superior efficacy and its
low toxicity, while providing residual protection without promoting bacterial
resistance. As pressure mounts in the US and abroad for environmentally sound
technologies to address global health concerns, we feel that PURE is
well-positioned to supply SDC as a prime solution to multiple markets
including household, institutional, healthcare, personal care, textiles,
industrial fluids, water treatment, agriculture and food processing."

During the quarter, the United States Patent and Trademark Office issued
patent number 7,435,438, which covers PURE's process for treating consumable
food products with silver dihydrogen citrate (SDC) to reduce or eliminate
microbial contamination. The new patent expands the scope of protection of
PURE's core technology patent, US Patent 6,197,814, covering the composition
and method of making of PURE's silver dihydrogen citrate (SDC) antimicrobial.

Subsequent to the quarter's end, in November PURE announced a new
agreement with Ciba (SWX: CIBN) to market and sell PURE's silver dihydrogen
citrate antimicrobial as a natural preservative and biocide in the personal
care, household, and industrial markets worldwide. In the personal care
market, PURE granted Ciba exclusive marketing rights for SDC under the trade
name Ciba(R) TINOSAN(R) SDC.

"We continue to work on a number of important alliances and major market
opportunities and expect that these efforts will be successful on an ongoing
basis," Krall concluded.

About PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience products
that provide solutions to numerous global health challenges, including Staph
(MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies,
including its silver dihydrogen citrate-based antimicrobials, represent
innovative advances in diverse markets and lead today's global trend toward
industry and consumer use of "green" products while providing competitive
advantages in efficacy and safety. Patented SDC is an electrolytically
generated source of stabilized ionic silver which formulates well with other
compounds. As a platform technology, SDC is distinguished from competitors in
the marketplace because of its superior efficacy, reduced toxicity and the
inability of bacteria to form a resistance to it. PURE is headquartered in El
Cajon, California (San Diego metropolitan area). Additional information on
PURE is available at http://www.purebio.com.

This press release includes statements that may constitute
"forward-looking" statements, usually containing the words "believe,"
"estimate," "project," "expect" or similar expressions. These statements are
made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements inherently involve
risks and uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or contribute to
such differences include, but are not limited to, acceptance of the Company's
current and future products and services in the marketplace, the ability of
the Company to develop effective new products and receive regulatory approvals
of such products, competitive factors, dependence upon third-party vendors,
and other risks detailed in the Company's periodic report filings with the
Securities and Exchange Commission. By making these forward-looking
statements, the Company undertakes no obligation to update these statements
for revisions or changes after the date of this release.

(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, ... with the grand opening of the Sober College Robert Pfeifer Memorial Learning Center ... December 2-3, and was attended by an overwhelming amount of alumni, family, colleagues ...

(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...

(Date:12/8/2016)... , ... December 08, 2016 , ... ... Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported local ... “This was our first franchise-wide Quack Gives Back initiative, and we’re ...

(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...

(Date:12/8/2016)... , Dec. 8, 2016 Eli Lilly and ... results of its phase 3 EXPEDITION3 trial at the ... meeting. As previously disclosed, solanezumab did not meet the ... of solanezumab initiated in people with mild dementia due ... regulatory submissions for solanezumab for the treatment of mild ...

(Date:12/8/2016)... Pa. , Dec. 8, 2016 Pennsylvania ... Secretary of Drug and Alcohol Programs Gary ... and insomnia medications, known as benzodiazepines, developed with ... "Benzodiazepines are medications that are frequently prescribed ... when they are used with opioid pain medications, ...